Search Results

AR-A014418 50mg  | Purity Not Available

Selleck Chemicals

AR-A014418 (GSK-3β Inhibitor VIII) is an ATP-competitive, and selective GSK3β inhibitor with IC50 and Ki of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.

More Information Supplier Page

AR-A014418 10mg  | Purity Not Available

Selleck Chemicals

AR-A014418 (GSK-3β Inhibitor VIII) is an ATP-competitive, and selective GSK3β inhibitor with IC50 and Ki of 104 nM and 38 nM in cell-free assays, without significant inhibition on 26 other kinases tested.

More Information Supplier Page

TAPI-1 5mg  | Purity Not Available

Selleck Chemicals

TAPI-1 is an ADAM17/TACE inhibitor, which blocks shedding of cytokine receptors. TAPI-1 is also an inhibitor of Matrix Metalloproteinase (MMP).

More Information Supplier Page

SB-3CT 100mg  | Purity Not Available

Selleck Chemicals

SB-3CT is an effective and selective gelatinase inhibitor with Ki of 13.9 nM and 600 nM for MMP-2 and MMP-9, respectively.

More Information Supplier Page

SB-3CT 25mg  | Purity Not Available

Selleck Chemicals

SB-3CT is an effective and selective gelatinase inhibitor with Ki of 13.9 nM and 600 nM for MMP-2 and MMP-9, respectively.

More Information Supplier Page

Z-FA-FMK 5mg  | Purity Not Available

Selleck Chemicals

Z-FA-FMK ((1S)-Z-FA-FMK) is an irreversible cysteine protease inhibitor, and also inhibits effector caspases.

More Information Supplier Page

Loxistatin Acid (E-64C) 5mg  | Purity Not Available

Selleck Chemicals

Loxistatin Acid (E-64C, NSC 694279, EP 475), a derivative of E-64, is an irreversible and membrane-permeant cysteine protease inhibitor. The cysteine protease cathepsin L is required for SARS-CoV-2 viral entry.

More Information Supplier Page

Aloxistatin (E64d) 2mg  | Purity Not Available

Selleck Chemicals

Aloxistatin (E64d) is an irreversible and membrane-permeable cysteine protease inhibitor with blood platelet aggregation inhibiting activity. The cysteine protease cathepsin L is required for SARS-CoV-2 viral entry, and aloxistatin treatment reduced cellular entry of SARS-CoV-2 pseudovirions by 92.3%.

More Information Supplier Page